AN UPDATE DATA ON THE TREATMENT OF CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (review of literature)

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a heterogeneous immune-mediated peripheral neuropathy with progressive or relapse-remitting course. Incidence of CIDP ranged between 1 and 8.9/100 000. Recently, most frequent therapies for CIDP treatment was glucocorticosteroids, intraveno...

Full description

Saved in:
Bibliographic Details
Main Authors: Roman A. Gapeshin, Evgeny R. Barantsevich, Dmitry I. Rudenko, Oksana V. Posokhina, Tima R. Stuchevskaya
Format: Article
Language:Russian
Published: Academician I.P. Pavlov First St. Petersburg State Medical University 2019-08-01
Series:Учёные записки Санкт-Петербургского государственного медицинского университета им. Акад. И.П. Павлова
Subjects:
Online Access:https://www.sci-notes.ru/jour/article/view/567
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chronic inflammatory demyelinating polyneuropathy (CIDP) is a heterogeneous immune-mediated peripheral neuropathy with progressive or relapse-remitting course. Incidence of CIDP ranged between 1 and 8.9/100 000. Recently, most frequent therapies for CIDP treatment was glucocorticosteroids, intravenous immunoglobulin and plasma exchange. In cases of ineffectiveness or lack of effectiveness, cytostatics, monoclonal antibodies and others could be used for CIDP treatment. In the article, authors presented an update data on the use of main methods for CIDP therapy, their mechanisms of action, indication for their use and advantages and disadvantages of each of them.
ISSN:1607-4181
2541-8807